Who Holds AgomAb Therapeutics NV (AGMB)? 34 Institutional Holders, Q2 2026
Managers with more than $100 million in US equities report their holdings on Form 13F within 45 days of each quarter end. Quarter ended 30 Jun 2026: 34 holders, $337 million in total.
Largest holders
The 34 largest by value. Change in shares against Q1 2026.
| Manager | Shares | Value | Change | |
|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $67 million | +0% | 13F |
| Sanofi | 2,783,096 | $36 million | +0% | 13F |
| Redmile Group, LLC | 2,733,926 | $35 million | +1650% | 13F |
| Cormorant Asset Management, LP | 2,465,348 | $32 million | +0% | 13F |
| TCG Crossover Management, LLC | 2,053,233 | $27 million | +0% | 13F |
| FEDERATED HERMES, INC. | 1,618,000 | $21 million | +0% | 13F |
| Nantahala Capital Management, LLC | 1,568,188 | $20 million | +31% | 13F |
| Casdin Capital, LLC | 1,550,000 | $20 million | +0% | 13F |
| ANDERA PARTNERS | 1,538,702 | $20 million | +0% | 13F |
| FMR LLC | 1,458,677 | $19 million | +0% | 13F |
| Aberdeen Group plc | 846,695 | $11 million | +20% | 13F |
| PERCEPTIVE ADVISORS LLC | 600,000 | $8 million | +0% | 13F |
| SAMSARA BIOCAPITAL, LLC | 600,000 | $8 million | +0% | 13F |
| Siren, L.L.C. | 411,250 | $5 million | +0% | 13F |
| ORBIMED ADVISORS LLC | 192,740 | $3 million | New | 13F |
| Pfizer Inc | 75,000 | $1 million | +0% | 13F |
| ALPS ADVISORS INC | 49,984 | $648,792 | New | 13F |
| Bellevue Group AG | 49,248 | $639,239 | -2% | 13F |
| SEVEN GRAND MANAGERS, LLC | 47,600 | $617,848 | -76% | 13F |
| SECTORAL ASSET MANAGEMENT INC | 43,500 | $564,630 | +0% | 13F |
| Burkehill Global Management, LP | 35,000 | $454,300 | +0% | 13F |
| Quadrature Capital Ltd | 20,461 | $265,584 | New | 13F |
| TWO SIGMA INVESTMENTS, LP | 18,072 | $234,575 | +27% | 13F |
| GOLDMAN SACHS GROUP INC | 11,800 | $153,164 | -67% | 13F |
| XTX Topco Ltd | 10,271 | $133,318 | New | 13F |
| CITIGROUP INC | 9,496 | $123,258 | New | 13F |
| UBS Group AG | 2,128 | $27,622 | -67% | 13F |
| GAMMA Investing LLC | 1,344 | $17,445 | New | 13F |
| MORGAN STANLEY | 1,200 | $15,576 | -60% | 13F |
| BNP PARIBAS FINANCIAL MARKETS | 754 | $9,787 | New | 13F |
| Larson Financial Group LLC | 698 | $9,060 | New | 13F |
| HRT FINANCIAL LP | 17,075 | $221 | -28% | 13F |
| Caitong International Asset Management Co., Ltd | 2 | $26 | New | 13F |
| SBI Securities Co., Ltd. | 2 | $26 | +0% | 13F |
Questions and answers
- How many institutions hold AgomAb Therapeutics NV?
- 34 managers reported AgomAb Therapeutics NV on Form 13F for the quarter ended 30 June 2026, against 32 the quarter before.
- Who is the largest institutional holder of AgomAb Therapeutics NV?
- EQT Fund Management S.a r.l., with 5,141,992 shares worth $67 million on its 13F for Q2 2026.
- How many institutions bought or sold out of AgomAb Therapeutics NV in Q2 2026?
- 9 managers reported a new position and 7 reported none after holding it the quarter before.
Source: SEC EDGAR, Form 13F (public domain). Counts and values as filed. Cite this page: Tamarly Intelligence, "Who holds AgomAb Therapeutics NV, Q2 2026", https://app.tamarly.ai/holders/agomab-therapeutics, built from SEC EDGAR.
Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.